Supplementary Table S3 from Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Authors:Ziao Li, Sudeh Izadmehr, Jeannie Hoffman-Censits et al.
<jats:p><p>Table S3 shows detailed power calculation.</p></jats:p>
Keywords
ptableshowsdetailedpowercalculationp
Related Articles
Plant-Derived Flavonoids as Multi-Target Pharmacological Modulators: Mechanisms, Therapeutic Potential and Translational Challenges in Acute and Chronic Diseases